Visterra (PRIVATE.VIST)

Overall impact
B (63)

Commentary

Visterra is a strong overall performer. With a 'B' rating of 63.2 for overall impact (70th percentile compared to all companies), Visterra ranks 370th out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 366 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 212 others. On top material causes for Visterra's industry (Pharmaceuticals & Biotech), Visterra performs well in Technology Innovation (95.1 score), Access to Affordable Healthcare (95.5), Disease Eradication (96.2) and 1 other cause where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (32.0 score), Child and Maternal Health (13.6), Decent, Safe Work Opportunities (34.3) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.VIST
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Visterra

Employees
122
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Massachusetts, United States
Share classes
PRIVATE.VIST
Description
Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The company's novel platform designs and engineers antibody-based biological products for the treatment of non-infectious diseases that are not being adequately addressed. This approach enables the patients to seek the significant unmet need for effective therapies.
Material causes
Ethos considers the following causes material for Visterra, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.